Recent Updates
Recently added Catalysts
ICCC Positive Sentiment Score: 65/100

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023

Thursday, May 4, 2023 2 min read
Key Takeaway: ImmuCell Corporation is preparing to report its unaudited financial results for the quarter that ended on March 31, 2023. The report is expected to be released after market close on May 11, 2023, followed by a conference call on May 12 to discuss the results. The company anticipates no changes to its preliminary sales results disclosed earlier. Additionally, ImmuCell continues its efforts in developing innovative products to enhance animal health.

Market Sentiment Analysis

POSITIVE FACTORS

  • ImmuCell is advancing its product offerings for animal health.
  • The company is expected to disclose its financial results soon, indicating transparency.
  • There is strong anticipation for the development of Re-Tain®, a novel treatment with no milk discard requirement.

Full Press Release Details

PORTLAND, Maine, May 04, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2023 after the market closes on Thursday, May 11, 2023.
The Company has scheduled a conference call the next morning, Friday, May 12, 2023, at 9:00 AM ET to review its first quarter financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until May 19, 2023 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #3163870.
The Company expects to file its Quarterly Report on Form 10-Q after the market closes on Thursday, May 11, 2023. The Company anticipates no change to the preliminary sales results for the first quarter of 2023 that were disclosed on April 5, 2023.
Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which can be accessed under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company, after the market closes on Thursday, May 11, 2023.
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef calves.  ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
Michael F. Brigham, President and CEO
ImmuCell Corporation
Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LLC
iccc@lythampartners.com

Frequently Asked Questions

When will ImmuCell report Q1 financial results?

ImmuCell will report its unaudited financial results on May 11, 2023.

What time is the ImmuCell conference call?

The conference call is scheduled for May 12, 2023, at 9:00 AM ET.

How can I access the conference call?

Dial (844) 855-9502 for toll-free or (412) 317-5499 for international access.

What products does ImmuCell offer?

ImmuCell offers First Defense® for calves and is developing Re-Tain® for mastitis.

Where can I find ImmuCell’s corporate presentation?

The presentation is available under the ‘Investors’ tab on ImmuCell's website.

Tags: ICCC Viatris Investor Conferences Healthcare animal health Re-Tain financial results quarterly report
Last updated: May 4, 2023